Carla van Herpen

3.5k total citations · 1 hit paper
29 papers, 1.9k citations indexed

About

Carla van Herpen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carla van Herpen has authored 29 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carla van Herpen's work include Lung Cancer Treatments and Mutations (6 papers), Renal cell carcinoma treatment (5 papers) and Renal and related cancers (5 papers). Carla van Herpen is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Renal cell carcinoma treatment (5 papers) and Renal and related cancers (5 papers). Carla van Herpen collaborates with scholars based in Netherlands, United States and United Kingdom. Carla van Herpen's co-authors include Thierry Gorlia, Jacques Bernier, Jean-Louis Lefèbvre, Didier Cupissol, John S. Stewart, H. Kienzer, M. Degardin, S. Jelić, Daniëlle Van den Weyngaert and Jan B. Vermorken and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Carla van Herpen

28 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

2007 1.2k citations Carla van Herpen et al. profile →

Peers

Countries citing papers authored by Carla van Herpen

Since Specialization

Citations

This map shows the geographic impact of Carla van Herpen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carla van Herpen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carla van Herpen more than expected).

Fields of papers citing papers by Carla van Herpen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carla van Herpen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carla van Herpen. The network helps show where Carla van Herpen may publish in the future.

Co-authorship network of co-authors of Carla van Herpen

This figure shows the co-authorship network connecting the top 25 collaborators of Carla van Herpen. A scholar is included among the top collaborators of Carla van Herpen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carla van Herpen. Carla van Herpen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	10
2	Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors 2023 ·Biomedicine & Pharmacotherapy ·(unknown), Ron H.J. Mathijssen, Job van Riet, Neeltje Steeghs, Mariëtte Labots, Carla van Herpen, Lot A. Devriese, Vivianne C. G. Tjan‐Heijnen, Emile E. Voest, Stefan Sleijfer, John W.M. Martens, Edwin Cuppen, Harmen J.G. van de Werken, Sander Bins	3
3	A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Neeltje Steeghs, (unknown), Carla van Herpen, (unknown), John F. Redman, Xiaofei Zhou	2
4	Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer 2019 ·Head & Neck ·Špela Miroševič, Belinda Thewes, Carla van Herpen, J.H.A.M. Kaanders, Matthias A.W. Merkx, Gerry Humphris, Robert J. Baatenburg de Jong, Johannes A. Langendijk, C. René Leemans, Chris H.J. Terhaard, Irma M. Verdonck‐de Leeuw, Robert P. Takes, Judith B. Prins	29
5	Pulmonary Lymphangitis Carcinomatosis of Clear Cell Renal Cell Carcinoma After Angiogenesis Inhibition 2018 ·Gürsah Kats‐Ugurlu, Carla van Herpen, Sasja F. Mulder, Mathias Prokop, (unknown), Peter F.A. Mulders, (unknown), J. Han van Krieken, Egbert Oosterwijk, William P. J. Leenders, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
6	Impact of CYP3A422 on Pazopanib Pharmacokinetics in Cancer Patients 2018 ·Clinical Pharmacokinetics* ·Sander Bins, Alwin D. R. Huitema, (unknown), Samira El Bouazzaoui, Huixin Yu, (unknown), Carla van Herpen, Paul Hamberg, Hans Gelderblom, Neeltje Steeghs, Stefan Sleijfer, Ron H. N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen	24
7	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial 2017 ·European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Bernard Escudier, Piotr Rutkowski, Alan Anthoney, Sebastian Bauer, Jozef Šufliarský, Carla van Herpen, Lars H. Lindner, Viktor Grünwald, Branko Zakotnik, Evelyne Lerut, Maria Dêbiec‐Rychter, Sandrine Marréaud, Michela Lia, Tiana Raveloarivahy, Sandra Collette, Laurence Albigès	94
8	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies 2016 ·Clinical Therapeutics ·Luc Dirix, Helen Swaisland, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jérusalem, Christian Rolfo, Dorte Nielsen, L. Rhoda Molife, Rebecca Kristeleit, Judith de Vos‐Geelen, Morten Mau‐Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Anitra Fielding, Karen So, Wendy Bannister, Ruth Plummer	47
9	Intestinal‐type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment 2016 ·Head & Neck ·Ann Hoeben, (unknown), Frank Hoebers, Kenneth W. Kross, C.M.L. Driessen, Pieter J. Slootweg, V.C.G. Tjan-Heijnen, Carla van Herpen	30
10	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients 2015 ·Clinical Cancer Research ·Fabian Birzele, Edgar Voß, Adam Nopora, Konrad Honold, Florian Heil, (unknown), Henk M.W. Verheul, Christophe Le Tourneau, Jean‐Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valérie Méresse, Stefan Weigand, Valeria Runza, Michael A. Cannarile	45
11	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies. 2015 ·Journal of Clinical Oncology ·Elizabeth Ruth Plummer, Henk M.W. Verheul, Sylvie Rottey, Karin Leunen, Guy Jérusalem, Christian Rolfo, Dorte Nielsen, L Rhoda Molife, Rebecca Kristeleit, Judith de Vos‐Geelen, Morten Mau‐Sørensen, Patricia M.M.B. Soetekouw, Carla van Herpen, Helen Swaisland, Anitra Fielding, Karen So, Wendy Bannister, Luc Dirix	1
12	Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061 2015 ·Oncology ·Linda Cerbone, Cora N. Sternberg, Lisa Sengeløv, Mads Agerbæk, Carla van Herpen, Sandrine Marréaud, Sandra Collette, Jianping Zhang, Gedske Daugaard	25
13	Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments 2014 ·Neoplasia ·Gürsah Kats‐Ugurlu, Egbert Oosterwijk, Stijn Muselaers, Jeannette Oosterwijk‐Wakka, Christina Hulsbergen‐van de Kaa, (unknown), J. Han van Krieken, Ingrid M.E. Desar, Carla van Herpen, Cathy Maass, Rob de Waal, Peter F.A. Mulders, William P. J. Leenders	15
14	Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. 2013 ·Journal of Clinical Oncology ·Gedske Daugaard, Lisa Sengeløv, Mads Agerbæk, Cora N. Sternberg, Carla van Herpen, Sandra Collette, Sandrine Marréaud	8
15	Modest improvement in 20years of kidney cancer care in the Netherlands 2012 ·European Journal of Cancer ·S.A.M. van de Schans, Katja K.H. Aben, Peter F.A. Mulders, John B.A.G. Haanen, Carla van Herpen, Rob H.A. Verhoeven, Henrike E. Karim‐Kos, Egbert Oosterwijk, Lambertus A. Kiemeney	8
16	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs). 2012 ·Journal of Clinical Oncology ·Paul Hamberg, Marye J. Boers‐Sonderen, Walter J. Loos, Maja J. De Jonge, Winette T.A. van der Graaf, (unknown), Ferry A.L.M. Eskens, Jaap Verweij, Carla van Herpen, Stefan Sleijfer	2
17	Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. 2012 ·Journal of Clinical Oncology ·Paolo A. Ascierto, Carola Berking, Sanjiv S. Agarwala, Dirk Schadendorf, Carla van Herpen, Paola Queirolo, Christian U. Blank, Axel Hauschild, J. Thaddeus Beck, Angela Zubel, (unknown), Simon Wandel, Reinhard Dummer	40
18	Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): First results 2011 ·Rafke Schoffelen, Otto C. Boerman, Winette van der Graaf, Carla van Herpen, Robert M. Sharkey, William J. McBride, Chien‐Hsing Chang, (unknown), David Goldenberg, Wim J.G. Oyen	6
19	Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours 2009 ·Acta Oncologica ·Ingrid M.E. Desar, (unknown), (unknown), Mireille Cantarini, Winette van der Graaf, Michelle van Rossum, Carla van Herpen	4
20	A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck 2007 ·Cancer Research ·J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra, Carla van Herpen, Chonlakiet Khorprasert, Denis Soulières, P Vodvářka, Danny Rischin, (unknown), Serban Ghiorghiu, Laura Hargreaves, Alison Armour, Everett E. Vokes	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact